- Sanofi (SNY -0.2%) has apparently suspended recruitment in its studies testing the use of malaria med hydroxychloroquine in COVID-19 patients.
- Developing...
- Update: France, Italy and Belgium have paused a large study of the drug following an earlier WHO decision to do the same. The European Medicines Agency (EMA) continues to caution on the drug's safety profile, reiterating its position that its use should be restricted to clinical trials and emergency use programs while further analyses are done.
- U.S. hospitals have backed away also. Orders have dropped 90% from the late-March peak to ~125K pills last week according to drug buyer Vizient.